Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Sulzmaier FJ
16-hexaoxo-3-phenylicosahydropyrrolo[1
CAS Number: 554435-83-5
VU-0357121 has the ability to enhance glutamate sensitivity of mGlu5 is likely due to the interaction at a site on the receptor distinct from the MPEP binding site
nor on components of the ERK
Empagliflozin - CAS# 864070-44-0 Catalog No.:M10131-10 Sulzmaier FJEmpagliflozin, also known as BI10773 (trade name Jardiance), is drug approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), which is